Pharmacological management of elevated LDL in patients with hypercholesterolaemia and mixed dyslipidaemia - PubMed
2 hours ago
- #hypercholesterolemia
- #PCSK9-inhibitors
- #LDL-C
- LDL-C is the major lipid target to reduce ASCVD risk in hypercholesterolemia and mixed dyslipidemia.
- Lifestyle and diet modifications are the first approach, but pharmacological intervention is often necessary.
- Statins are the primary therapy for LDL-C reduction but may not achieve aggressive targets alone.
- Ezetimibe and bempedoic acid are recommended as add-on or alternative oral therapies.
- PCSK9 inhibitors are highly effective but face challenges due to cost and injection reluctance.
- Oral PCSK9 inhibitors and obicetrapib in development show promise as future alternatives.
- Long-term adherence to therapy remains a significant challenge.